Purple Biotech (PPBT) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | PPCB |
|---|---|---|
| Share price | $1.53 | $1.78 |
| Market cap | $1.86M | $1.87M |
| 1-day change | -4.09% | +3.19% |
| EPS (TTM) | $-47.64 | $-95.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-26.39M | $-18.86M |
| 52-week high | $8.90 | $315.00 |
| 52-week low | $0.91 | $1.61 |
| Distance from 52-week high | -82.87% | -99.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +1014.75% | — |
| Average volume | 1.26M | 188.66K |
| Shares outstanding | 1.22M | 1.05M |
| Employees | 10 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PPBT vs PPCB FAQ
Which is bigger, Purple Biotech or Propanc Biopharma?
Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.86M for Purple Biotech (PPBT).
Are Purple Biotech and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.